GGrantIndex
← Leaderboards

Kian H Lim

Washington University

Google Scholar ↗PubMed ↗ORCID ↗
$7,461,157
Attributed
$9,305,735
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.7M · FY2018–25
$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$13,575,345 · 8

By mechanism

P50$5,202,899 · 2
R01$4,951,440 · 3
R37$2,422,136 · 1
U54$639,984 · 1
R21$358,886 · 1

Top collaborators

Most similar at Washington University

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Clinical Trials”

Research focus

Clinical TrialsMalignant Neoplasm Of PancreasMalignant NeoplasmsPancreatic Ductal AdenocarcinomaChemotherapySignal TransductionMouse ModelGeneticTumorRegimenResistanceFutureBiologyPre-ClinicalCancer TypeNovel TherapeuticsResponseInhibitorTumor MicroenvironmentTreatment ResponseEffective TherapyIn VivoClinicCells

Grant awards (27)

Washington University SPORE in Pancreatic Cancer$2,178,396
P50 · FY2025 · CA
Harnessing TNFa Signaling To Improve Therapeutic Response In Pancreatic Cancer$602,576
R01 · FY2025 · CA · contact PI
Targeting tumor innate immune signaling in pancreatic cancer$391,277
R01 · FY2025 · CA · contact PI
Project 3: Targeting Stress-induced MK2 as Novel Strategy in Pancreatic Cancer$291,646
P50 · FY2025 · CA · contact PI
Research Project 2$209,902
U54 · FY2025 · CA · contact PI
Washington University SPORE in Pancreatic Cancer$2,091,214
P50 · FY2024 · CA
Harnessing TNFa Signaling To Improve Therapeutic Response In Pancreatic Cancer$572,447
R01 · FY2024 · CA · contact PI
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA$337,922
R37 · FY2024 · CA · contact PI
Project 3: Targeting Stress-induced MK2 as Novel Strategy in Pancreatic Cancer$282,552
P50 · FY2024 · CA · contact PI
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy$252,589
R01 · FY2024 · CA
Research Project 2$199,164
U54 · FY2024 · CA · contact PI
Harnessing TNFa Signaling To Improve Therapeutic Response In Pancreatic Cancer$618,273
R01 · FY2023 · CA · contact PI
Project 3: Targeting Stress-induced MK2 as Novel Strategy in Pancreatic Cancer$359,091
P50 · FY2023 · CA · contact PI
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA$350,460
R37 · FY2023 · CA · contact PI
Research Project 2$230,918
U54 · FY2023 · CA · contact PI
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy$168,482
R01 · FY2023 · CA
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy$591,868
R01 · FY2022 · CA
IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma$348,844
R37 · FY2022 · CA · contact PI
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy$597,298
R01 · FY2021 · CA
IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma$348,844
R37 · FY2021 · CA · contact PI
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy$580,914
R01 · FY2020 · CA
IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma$348,844
R37 · FY2020 · CA · contact PI
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy$575,716
R01 · FY2019 · CA
IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma$338,378
R37 · FY2019 · CA · contact PI
Evaluation of IRAK4 As A Novel Therapeutic Target in Colorectal Cancer$193,042
R21 · FY2019 · CA · contact PI
IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma$348,844
R37 · FY2018 · CA · contact PI
Evaluation of IRAK4 As A Novel Therapeutic Target in Colorectal Cancer$165,844
R21 · FY2018 · CA · contact PI